Akso Health Group ADR (AHG) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Akso Health Group ADR stock (AHG) is currently trading at $2.37. Akso Health Group ADR PS ratio (Price-to-Sales) is 136.22. WallStSmart rates AHG as Sell.
- AHG PE ratio analysis and historical PE chart
- AHG PS ratio (Price-to-Sales) history and trend
- AHG intrinsic value — DCF, Graham Number, EPV models
- AHG stock price prediction 2025 2026 2027 2028 2029 2030
- AHG fair value vs current price
- AHG insider transactions and insider buying
- Is AHG undervalued or overvalued?
- Akso Health Group ADR financial analysis — revenue, earnings, cash flow
- AHG Piotroski F-Score and Altman Z-Score
- AHG analyst price target and Smart Rating
Akso Health Group ADR
📊 No data available
Try selecting a different time range
Smart Analysis
Akso Health Group ADR (AHG) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Akso Health Group ADR (AHG) Key Strengths (1)
Revenue surging 415.80% year-over-year
Akso Health Group ADR (AHG) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Very expensive at 136.2x annual revenue
Very expensive at 10.0x book value
Very low institutional interest at 0.03%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Akso Health Group ADR (AHG) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 415.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (136.22), Price/Book (10.04) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -80.30%, Operating Margin at -43.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -80.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 415.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AHG Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AHG's Price-to-Sales ratio of 136.22x sits near its historical average of 151.23x (64th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 90% below its historical high of 1323.76x set in Oct 2021, and 4079% above its historical low of 3.26x in Mar 2020. Over the past 12 months, the PS ratio has compressed from ~268.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Akso Health Group ADR (AHG) · HEALTHCARE › MEDICAL DISTRIBUTION
The Big Picture
Akso Health Group ADR is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 15M with 416% growth year-over-year.
Key Findings
Revenue growing at 416% YoY, reaching 15M. This pace significantly outperforms most MEDICAL DISTRIBUTION peers.
Generating 3M in free cash flow and 3M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Growth sustainability: can Akso Health Group ADR maintain 416%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DISTRIBUTION industry trends, competitive moves, and regulatory changes that could impact Akso Health Group ADR.
Bottom Line
Akso Health Group ADR is a high-conviction growth story with revenue accelerating at 416% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Akso Health Group ADR(AHG)
NASDAQ
HEALTHCARE
MEDICAL DISTRIBUTION
China
Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and integrated patient care services. With a specialization in advanced health technologies, the company is well-positioned to tap into growth opportunities in telehealth and personalized medicine, bolstered by a strong commitment to research and development. Its robust business model and dedication to quality, supported by a skilled team of professionals, make Akso Health Group an appealing investment for institutional investors aiming to navigate the transformative landscape of healthcare.